SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-000943
Filing Date
2019-01-03
Accepted
2019-01-02 21:57:37
Documents
8
Period of Report
2018-12-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d681717d8k.htm 8-K 44885
2 EX-10.1 d681717dex101.htm EX-10.1 754647
3 GRAPHIC g681717dsp46.jpg GRAPHIC 2556
4 GRAPHIC g681717dsp47.jpg GRAPHIC 3101
5 GRAPHIC g681717dsp48.jpg GRAPHIC 3154
6 GRAPHIC g681717dsp49.jpg GRAPHIC 3460
7 GRAPHIC g681717dsp51a.jpg GRAPHIC 2819
8 GRAPHIC g681717dsp51b.jpg GRAPHIC 4206
  Complete submission text file 0001193125-19-000943.txt   828520
Mailing Address 300 GEORGE STREET SUITE 301 NEW HAVEN CT 06511
Business Address 300 GEORGE STREET SUITE 301 NEW HAVEN CT 06511 312 767 0291
MELINTA THERAPEUTICS, INC. /NEW/ (Filer) CIK: 0001461993 (see all company filings)

IRS No.: 454440364 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35405 | Film No.: 19503547
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences